Free shipping on all orders over $ 500

Palbociclib

Cat. No. M6167
Palbociclib Structure
Synonym:

PD 0332991

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 80 In stock
50mg USD 200 In stock
100mg USD 360 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: The IC50 of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser780 in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser795 in this tumor with an IC50 of 63 nM, and similar effects on both Ser780 and Ser795 phosphorylation are obtained in the Colo-205 colon carcinoma. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC50s are 0.01 µM, 0.01 µM, 0.06 µM, and 0.6 µM, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC50>10 µM). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 µM induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 µM, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05).

In vivo: Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose.

Product Citations
Customer Product Validations & Biological Datas
Source Nature (2018). Figure 10. Palbociclib (Abmole Bioscience)
Method i.v.
Cell Lines C57BL/6 mice
Concentrations 150 mg/kg body weight
Incubation Time 7 days
Results Notably, we observed that treatment of immunoproficient mice bearing CT26 tumors with palbociclib plus anti-PD-1 antibody dramatically retarded tumor progression and resulted in 8 complete responses out of 12 treated mice.
Source Nature (2018). Figure 9. Palbociclib (Abmole Bioscience)
Method IB analysis
Cell Lines 293T cells
Concentrations 1 μM
Incubation Time 12 h
Results Conversely, treatment of cells with CDK4/6 inhibitor, palbociclib, reduced the phosphorylation of SPOP in cells.
Source Nature (2018). Figure 3. Palbociclib (Abmole Bioscience)
Method Immunoblot (IB) analysis
Cell Lines MC38 or B16-F10 mouse
Concentrations 150 mg/kg body weight
Incubation Time 7 days
Results We also observed that palbociclib treatment significantly elevated PD-L1 protein levels in various organs of normal mice
Source Nature (2018). Figure 2. Palbociclib (Abmole Bioscience)
Method IB analysis
Cell Lines MDA-MB-231 cells
Concentrations 0.5, 1 μM
Incubation Time 48 h
Results "Furthermore, treatment of multiple cancer cell lines with two different selective inhibitors of CDK4/6 kinase, palbociclib or ribociclib, upregulated PD-L1 protein abundance and stability even in pRB knock-down cells."
Protocol
Cell Experiment
Cell lines MRT cell lines
Preparation method Palbociclib (PD) is prepared in DMSO and stored (−80°C), and then diluted with appropriate media before use. MRT cell lines, G401, MP-MRT-AN (AN), KP-MRT-RY (RY), KP-MRT-NS (NS), and KP-MRT-YM (YM) cell lines are seeded in normal growth medium into 96-well cell plates. After 24 h, the culture medium is replaced with culture medium containing Palbociclib (0.05 or 1 µM) or DMSO.
Concentrations 0.05 or 1 µM
Incubation time 24 h
Animal Experiment
Animal models Mice
Formulation sodium lactate buffer
Dosages 150 or 75 mg/kg
Administration p.o.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 447.53
Formula C24H29N7O2
CAS Number 571190-30-2
Purity >98%
Solubility 0.2 mg/mL in DMSO
Storage at -20°C
References

Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS, et al. Ann Pharmacother. 2015 Nov;49(11):1252-60. PMID: 26324355.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, et al. N Engl J Med. 2015 Jul 16;373(3):209-19. PMID: 26030518.

Related CDK Products
THZ2

THZ2 (an analog of THZ1) is a potent and selective CDK7 inhibitor which overcomes the instability of THZ1 in vivo (IC50s: CDK7=13.9 nM; TNBC cells=10 nM).

LY-3177833

LY-3177833 is a potent and selective inhibitor of CDC7 with IC50 of 3.3 nM.

Voruciclib

Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively.

CVT-313

CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro.

ON123300

ON123300 is a potent inhibitor of CDK4, with an IC50 of 3.8 nM, with little inhibitory activity against CDKs 1,2,5 and 8.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Palbociclib, PD 0332991 supplier, CDK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.